CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
INCB018424 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00550043
NCT00550043Phase 2Completed
CompareCT.gov

A Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Incyte Corporation·interventional·Posted Oct 26, 2007·Updated Mar 23, 2015

In Brief

A Phase 2 clinical trial evaluating INCB018424 and Placebo for Rheumatoid Arthritis. Completed, enrolled 50 participants across 15 sites in 2 countries.

Detailed Summary

The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesPoland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2007
Enrollment StartOct 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.7 years ago

Interventions

INCB018424drug

Placebodrug